ECONOMIC BURDEN OF BIOSIMILAR DELIVERY IN FRANCE- REAL WORLD ANALYSIS FROM THE PERMANENT SAMPLE OF NATIONAL HEALTH INSURANCE BENEFICIARIES, BETWEEN 2007 TO 2017
Author(s)
Parmentier R1, Blein C2, Borget I3, Bocquet F4, Daydé F5, Chaize G6, Reymond F7, Chouaid C8
1CHU Grenoble-Alpes, Paris, France, 2Creativ-Ceutical, lyon, 69, France, 3Univ Paris-Sud, Faculty of Pharmacy, GRADES, VILLEJUIF, France, 4Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France; Health Law Institute, Inserm, UMR S 1145, Paris Descartes Université, Sorbonne Paris Cité, Paris, France, Paris, France, 5HEVA, Lyon, France, 6HEVA, lyon, France, 7CHU Grenoble-Alpes, Grenoble cedex 9, France, 8Department of Chest Medicine, Créteil University Hospital, Créteil, France
Presentation Documents
OBJECTIVES Biosimilars drugs represent significant savings for the French National Insurance. The biologic drugs environment is challenging in France and health authorities create stronger incentives to encourage biosimilar prescription and the loss of patents has accelerated. The aim of the study is to analyszed the economic burden and the market share evolution of biosimilar drugs based on claims data “permanent sample of national health insurance” between 2007 (first biosimilar launch) and 2017. METHODS Retrospective observational study of biosimilars and reference products consumptions. We have extracted the health insurance reimbursement for all biosimilar and reference medicinal products commercialized in France during the period. Market shares were calculated by dividing the number of biosimilars packages delivered to all drug packages (biosimilar and references). Costs (in Euro) were extrapolated to national level by using coefficient published by the national health insurance office (CNAM). RESULTS : Consumptions of 11 biosimilars and 6 reference drugs were analyzed. Biosimilar expenditures were €0,7 billion compared to €6,5 billion for reference drugs. Biosimilar market shares increased from 4% to 19% between 2010 and 2017. Biosimilar drugs like filgrastim and epoetin had the most important expenditures (respectively €286 million and €186 million). In 2017, these same drugs had the most important market shares with respectively 80% and 63%. On the other side, biosimilar drugs like etanercept and insulin glargin had the smallest expenditures during the period (respectively €7,3 million and €7,2 million) and the smallest market share (4% each) in 2017. CONCLUSIONS : This study demonstrate that biosimilar drug market increased during the period. The “Health National Strategy » biosimilar objective for 2022: 80% of market share is achievable if the market keeps the actual trend. Patient’s characteristics description could be complementary to this study, to give more information to the biosimilar landscape.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PMU151
Disease
Biologics and Biosimilars